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Abstract
Inﬂuenza virus is prone to mutations that may alter the intensity
of subsequent waves of infection. In this study, we evaluated
whether outcomes were different in the two waves of the
inﬂuenza A (H1N1) 2009 pandemic in patients admitted to the
intensive-care unit. Age, gender, lag-time to presentation and
APACHE-II scores were similar in both waves. Although ventila-
tory requirements were similar (36/37 vs. 36/39), non-signiﬁcant
reductions in the durations (days) of ventilation (10.3 ± 8.0
vs. 7.8 ± 9.4, p 0.11) and hospitalization (14.9 ± 10.5 vs.
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12.3 ± 14.1, p 0.20) were observed in the second wave. The
clinical proﬁle and outcomes were not signiﬁcantly different
between the two waves among severely ill patients.
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Inﬂuenza pandemics tend to affect the planet in two, and
sometimes three, waves [1]. Because of mutations in the
viral genome [2], there is potential for variation between the
waves of an inﬂuenza pandemic. Such mutations could result
in the emergence of a more virulent strain [3] and a more
severe second wave of infection [4]. Other factors that could
alter the severity of the second wave are prior vaccination
and immunity gained during the ﬁrst wave [1]. Therefore, it
is important to characterize each wave of the infection indi-
vidually and compare them for differences.
The WHO announced the emergence of a novel inﬂuenza
virus in April 2009. By May 2009, they declared it to be a pan-
demic. By December 2009, in India alone, there were 26 039
conﬁrmed cases, with 967 deaths [5]. Unlike in the West, case
reporting in India peaked between September and December
2009, and declined by February 2010 [6]. A second peak was
noted between July and September 2010 in India [6].
Given this background, we studied the clinical characteris-
tics and outcomes of patients with severe inﬂuenza A
(H1N1) 2009 virus infection requiring intensive care in the
two waves. The study was conducted in a 24-bed medical
intensive-care unit (ICU) in a 2200-bed tertiary-care hospital
in South India. The ﬁrst wave was deﬁned from the incident
patient in our hospital (August 2009) until the cluster of
cases ceased to occur (December 2009). Between January
and June 2010, only 12 patients tested positive, and were
considered to be sporadic cases. The second wave occurred
between July and October 2010. The two waves paralleled
national data [6]. Only conﬁrmed cases of inﬂuenza A
(H1N1) 2009 virus infection were included in our study. A
case was deﬁned as a patient presenting with inﬂuenza-like
illness (ILI) or severe acute respiratory illness (i.e. ILI requir-
ing admission) who tested positive for inﬂuenza A H1N1
2009 virus in real-time RT-PCR of respiratory samples [7].
Data were collected prospectively in the ﬁrst wave as part
of a multicentre study of ICU patients (submitted paper), fol-
lowing Institutional Review Board approval. Data from the
second wave were collected retrospectively from ICU ﬂow
charts, case notes and electronic databases, after an Institu-
tional Review Board waiver had been obtained. Clinical char-
acteristics (age, sex, coexisting illnesses, symptoms, and day
of illness at the time of presentation), admission APACHE-II
and SOFA scores were recorded. The primary outcome was
mortality. Other outcomes included type and duration of
ventilation, need for dialysis and intensive care, and hospital
length of stay. Continuous data were analysed with indepen-
dent t-tests, and categorical data were analysed with the
Pearson chi-square test. Analysis was performed with Stata
Version 11.
During the ﬁrst wave, 966 patients presenting with ILI or
severe acute respiratory illness were tested for inﬂuenza A
(H1N1) 2009 virus; 1177 patients were tested during the
second wave. Of these, 29.8% (288/966) tested positive for
inﬂuenza A (H1N1) 2009 virus in the ﬁrst wave and 29%
(341/1177) in the second wave. The month-wise distribution
of seasonal and inﬂuenza A (H1N1) 2009 virus positives and
the proportion who tested positive for inﬂuenza A (H1N1)
2009 virus are shown in Fig. 1. Of those who tested positive
for inﬂuenza A (H1N1) 2009 virus, 12.8% (37/288) needed
ICU admission during the ﬁrst wave, and 11.4% (39/341)
required ICU admission during the second wave. The mean
ages of patients admitted to the ICU in both waves were
similar (34.1 ± 13 years and 36.2 ± 14.6 years). There was a
long lag-time from onset of ﬁrst symptom to presentation to
our hospital: 6.4 ± 3.2 days and 6.0 ± 3.4 days in the two
waves, respectively (p 0.72). The time from hospital admis-
sion to ICU transfer in case of deterioration was shorter in
the second wave (5.6 ± 6.0 days, n=9) than in ﬁrst wave
(10.3 ± 5.3 days, n = 4), although the difference was non-
signiﬁcant (p 0.10). APACHE II scores (15.4 ± 5.8 vs.
17.0 ± 8.5, p 0.16) were marginally higher in the second
wave. The need for ventilation (97% vs. 92%), duration of
ventilation (10.3 ± 8.0 vs. 7.8 ± 9.5 days, p 0.11) length of
ICU/hospital stay and mortality (56.8% vs. 48.7%) were simi-
lar in the two waves (Table 1).
To our knowledge, this is the ﬁrst study that has com-
pared the clinical proﬁle and outcomes of patients admitted
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to the ICU during the two waves of the inﬂuenza A (H1N1)
2009 pandemic. We observed that the clinical proﬁle and
outcomes were not different between the two waves among
severely ill patients. A study from the USA that included 23
ICU patients reported outcomes during the second wave of
the pandemic [8], but did not make comparisons with
patients treated in their institution during the ﬁrst wave. A
more recent study from Wisconsin [9] that compared
patients hospitalized with inﬂuenza A (H1N1) 2009 virus
infection during the two waves reported a four-fold increase
in hospitalization and a ﬁve-fold increase in death in the
second wave. Patients in the second wave were signiﬁcantly
older, presented earlier and received antiviral treatment
earlier than those in the ﬁrst wave [9].
In contrast, in our study, the age and lag-time to presenta-
tion to hospital were similar in both waves. Delayed presenta-
tion in our cohort, particularly in the second wave, is
surprising, given the increased awareness about the infection
among healthcare workers and public. The proportions of
patients who tested positive for inﬂuenza A (H1N1) 2009
virus were also similar in the two waves in our study. This
probably reﬂects the fact that government-initiated mass
vaccination occurred only during the second wave. The com-
parable hospital course, need for mechanical ventilation and
mortality in the two waves in our study is consistent with the
Wisconsin experience [9]. Our series is, however, different in
that it was restricted to patients who required ICU care. Fur-
thermore, in our series, over 90% of patients admitted to the
ICU needed ventilatory support. The higher mortality in our
patients than in the series from the USA [9] may reﬂect sicker
patients who presented late and were managed in limited-
resource settings. The shorter duration of ventilation and
hospital stay in the second wave (although the difference was
non-signiﬁcant), despite marginally higher APACHE-II scores,
may suggest a better understanding of the disease process
and its management during the latter part of the pandemic.
The ﬁndings of the study must, however, be interpreted in
light of the limitations of small sample size, single-institution
experience and location in a resource-limited setting.
TABLE 1. Clinical characteristics and outcomes of patients
admitted to the intensive-care unit (ICU) with severe inﬂu-
enza A(H1N1) 2009 virus infection during the ﬁrst wave
(August to December 2009) and second wave (July to
September 2010) of the inﬂuenza pandemic in South
India—a single-centre experience
Variable
Wave 1a
N = 37
Wave 2a
N = 39 p-value
Age (years), mean (SD) 34.1 (13.0) 36.2 (14.6) 0.26
Male/female ratio 12 : 25 19 : 20 0.17
Day of illness at the time of
testing, mean (SD)
6.4 (3.2) 6.0 (3.4) 0.72
Underlying risk factors
Pregnancy/postpartum status (%) 8 (21.6) 7 (18.0)
Underlying cardiovascular disease (%) 5 (13.5)b 2 (5.1)c
Patients on immunosuppressants (%) 4 (10.8) 4 (10.3)
Diabetes (%) 2 (5.4) 1 (2.6)
Morbid obesity (%) 2 (5.4) NA
Underlying respiratory disease (%) 1 (2.7) 1 (2.6)
Need for ventilation
Ventilated (%) 36 (97.3) 36 (92.3) 0.62
Not ventilated (%) 1 (2.7) 3 (7.7)
Type of ventilation
Only NIV or no ventilation (%) 12 (32.4) 10 (25.6) 0.64
NIV followed by invasive ventilation (%) 05 (13.5) 10 (25.6)
Invasive ventilation (%) 20 (54.1) 19 (48.7)
Duration of ventilation (days), mean (SD) 10.3 (8.0) 7.8 (9.5) 0.11
Admission SOFA score, mean (SD) 6.0 (2.8) 5.4 (3.3) 0.23
APACHE-II score, mean (SD) 15.4 (5.8) 17.0 (8.5) 0.16
Renal failure requiring dialysis (%) 7 (18.9) 8 (20.5) 1.0
Duration of ICU stay (days), mean (SD) 11.7 (8.6) 9.0 (11.0) 0.12
Duration of hospital stay (days),
mean (SD)
14.9 (10.5) 12.4 (14.2) 0.20
Mortality (%) 21 (56.8) 19 (48.7) 0.50
NA, not available; NIV, non-invasive ventilation; SD, standard deviation.
aWave 1 refers to August 2009 to December 2009; wave 2 refers to July 2010
to September 2010.
bFour patients had evidence of rheumatic heart disease; three of these were
diagnosed during the current admission. One patient had pre-existing ischaemic
heart disease.
cBoth patients had evidence of rheumatic heart disease; categorical values were
compared with Fisher’s exact test, and continuous variables with Student’s t-
test.
Month-wise distribution of patients diagnosed as influenza A(H1N1)2009 pandemic
infection and seasonal influenza in a single centre in South India
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FIG. 1. Graph showing the number of
patients who tested positive for inﬂuenza A
(H1N1) 2009 virus, who tested positive for
seasonal ﬂu, and who tested negative for both.
The proportion of patients presenting with
inﬂuenza-like illness who were tested and
found to be positive for inﬂuenza A (H1N1)
2009 virus is also shown.
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In conclusion, despite the potential for variability during the
different waves of an inﬂuenza pandemic, this study shows
that the two waves of the inﬂuenza pandemic in our institu-
tion resulted in similar outcomes in severely ill patients.
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